SAStacy P. Ardoin

Stacy P. Ardoin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stacy P. Ardoin has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Laura E. Schanberg

    Duke University Medical Center, Durham, NC

    2 shared publications
  • Christy Sandborg

    Stanford Children’s Health | Lucile Packard Children’s Hospital, Pediatric Rheumatology, 730 Welch Rd, Palo Alto, CA, 94304, USA

    1 shared publication
  • D. S. Pisetsky

    Division of Rheumatology and Immunology, Duke University Medical Center, Medical Research Service, Durham VA Hospital, Durham, NC, USA

    1 shared publication
  • David S Pisetsky

    Medical Research Service, Durham VA Hospital, Durham, North Carolina, 508 Fulton Street, Durham, NC 27705, USA

    1 shared publication
  • David S. Pisetsky

    1 shared publication
  • Deborah Kredich

    Division of Pediatric Rheumatology, Duke University Medical Center, NC

    1 shared publication

Latest Publications

  • Open Access

    Reply

    by Stacy P. Ardoin, Gregory Evans, Christy Sandborg, Huiman X. Barnhart, Laura E. Schanberg, for the Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators

  • Open Access

    The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation

    by Stacy P. Ardoin, David S. Pisetsky

    Cell death is critical to normal homeostasis, although this process, when increased aberrantly, can lead to the production of pro-inflammatory mediators promoting autoimmunity. Two novel intercellular mediators of inflammation generated during cell death are high mobility group box 1 (HMGB1) protein and microparticles (MPs). HMGB1 is a nuclear protein that functions in transcription when inside the nucleus but takes on pro-inflammatory properties when released during cell death. Microparticles are small, membrane-bound structures that extrude from cells when they die and contain cell surface proteins and nuclear material from their parent cells. MPs circulate widely throughout the vasculature and mediate long-distance communication between cells. Both MPs and HMGB1 have been implicated in the pathogenesis of a broad spectrum of inflammatory diseases, including the prototypic autoimmune conditions systemic lupus erythematosus and rheumatoid arthritis. Given their range of activity and association w...


  • Open Access

    Developments in the scientific understanding of lupus

    by Stacy P Ardoin, David S Pisetsky

    Systemic lupus erythematosus is a systemic autoimmune disease characterized by the production of antinuclear antibodies (ANAs). Recent research into human and murine lupus suggests that disease susceptibility results from genetic polymorphisms regulating immune responses as well as impairing the clearance of apoptotic cells. Because the products of dead cells, including nucleic acids, have immunologic activity, this situation can promote antigen-driven ANA responses. Furthermore, immune complexes of ANAs can drive the production of proinflammatory cytokines, inducing the 'interferon signature', and intensifying disease. Together, these findings point to new genetic and immunologic markers of disease as well as targets for new therapies.


  • Infliximab to Treat Chronic Noninfectious Uveitis in Children: Retrospective Case Series with Long-term Follow-up

    by Stacy P. Ardoin, Deborah Kredich, Egla Rabinovich, Laura E. Schanberg, Glenn J. Jaffe


  • The Role of Microparticles in Inflammation and Thrombosis

    by S. P. Ardoin, J. C. Shanahan, D. S. Pisetsky

    Microparticles (MP) are small membrane‐bound vesicles that circulate in the peripheral blood and play active roles in thrombosis, inflammation and vascular reactivity. While MP can be released from nearly every cell type, most investigation has focused on MP of platelet, leucocyte and endothelial cell origin. Cells can release MP during activation or death. Flow cytometry is the usual method to quantify MP; the small size of these structures and lack of standardization in methodology complicate measurement. As MP contain surface and cytoplasmic contents of the parent cells and bear phosphatidylserine, antibodies to specific cell surface markers and annexin V can be used for identification. Through various mechanisms, MP participate in haemostasis and have procoagulant potential in disease. MP contribute to inflammation via their influence on cell–cell interactions and cytokine release, and MP also function in mediating vascular tone. In several disease states characterized by inflammation and vascular dysfunction, MP subpopulations are elevated, correlate with clinical events, and may have important roles in pathogenesis. In the rheumatic conditions such as rheumatoid arthritis and systemic lupus erythematosus, MP are potentially important markers of disease activity and have an increasingly recognized role in immunopathogenesis. It is clear that MP play an important role in atherosclerosis, and study of these structures may provide insight into the link between chronic inflammatory conditions and accelerated atherosclerosis. As biomarkers, MP allow access to usually inaccessible tissues such as the endothelium. Further research will hopefully lead to interventions targeting MP release and function.